Evidence map›Paper›PMID 19133134›Full record

ArticleJournal of inflammation (London, England)2009

Polyphenol-rich pomegranate fruit extract (POMx) suppresses PMACI-induced expression of pro-inflammatory cytokines by inhibiting the activation of MAP Kinases and NF-kappaB in human KU812 cells.

Zafar Rasheed, Nahid Akhtar, Arivarasu N Anbazhagan, Sangeetha Ramamurthy, Meenakshi Shukla, Tariq M Haqqi

Open access · goldAbstract read
In one paragraph

Article in Journal of inflammation (London, England), 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 55 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
55citing papers in PubMed, 1 pooled it
7.4field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

55 citing papers in PubMed, 1 synthesis or guideline pooled it, 154 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Review
  6. Antidepressant-like effects of theFrontiers in pharmacology · 2023
    Article
  7. Article
  8. Application of the Extracts ofDentistry journal · 2022
    Article
  9. Pomegranate (Foods (Basel, Switzerland) · 2022
    Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Zafar RasheedDepartment of Pathology, Microbiology, & Immunology, School of Medicine, University of South Carolina, 6439 Garners Ferry Road, Columbia, SC-29209, USA. Tariq.Haqqi@uscmed.sc.edu.
Nahid Akhtar
Arivarasu N Anbazhagan
Sangeetha Ramamurthy
Meenakshi Shukla
Tariq M Haqqi
University of South Carolina · USCase Western Reserve University · US

Funding

MECHANISMS OF CHONDROPROTECTION BY POMEGRANATE FRUIT EXTRACTR01AT003627 · NCCIH · UNIVERSITY OF SOUTH CAROLINA AT COLUMBIA · PI HAQQI, TARIQ M · 2007 to 2011
$1.7M
NCCIH NIH HHS R01 AT003627
6 · The paper itself

Abstract

backgroundMast cells and basophils are multifunctional effector cells and contain plentiful secretary granules in their cytoplasm. These cell types are involved in several inflammatory and immune events and are known to produce an array of mediators including a broad spectrum of cytokines. Pomegranate fruit is rich in anthocyanins and hydrolysable tannins; a group of polyphenolic compounds shown to be potent antioxidant with anti-inflammatory activity. However, no studies have been undertaken to investigate whether a polyphenol-rich pomegranate fruit extract (POMx) inhibits the inflammatory activity of activated human mast cells and basophils. The aim of this study was to examine whether POMx modulates inflammatory reactions using human basophilic cell line KU812.

methodsKU812 cells were stimulated with phorbol-12-myristate 13-acetate plus calcium inophore A23187 (PMACI). The inhibitory effect of POMx on pro-inflammatory cytokine gene expression and production by stimulated KU812 cells was measured by quantitative RT-PCR, and cytokine-specific ELISA assays, respectively. Western blotting was used to analyze the effect of POMx on the activation of mitogen-activated protein kinases (MAPKs), and the nuclear factor (NF)-kappaB in PMACI stimulated KU812 cells. Effect on the activity of NF-kappaB was determined using Luciferase reporter assay. Significance of differences from control values were analyzed by means of standard statistical methods.

resultsPOMx significantly decreased PMACI stimulated inflammatory gene expression and production of interleukin (IL)-6 and IL-8 in KU812 cells. The inhibitory effect of POMx on the pro-inflammatory cytokines was MAPK subgroups c-jun N-terminal kinase (JNK)- and extracellular-regulated kinase (ERK) dependent. In addition, POMx suppressed the NF-kappaB activation induced by PMACI by inhibiting IkappaB-degradation in human basophil cells. POMx also suppressed the powerful induction of NF-kappaB promoter-mediated luciferase activity in transiently transfected KU812 cells.

conclusionThese novel pharmacological actions of POMx provide new suggestion that POMx or POMx-derived compounds may be of therapeutic use for the treatment of inflammatory diseases by suppressing mast cells/basophils activation.

Identifiers

PMID19133134
PMCPMC2625340
OpenAlexW2051495414

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.